Inflammatory bowel disease in the setting of autoimmune pancreatitis

Ravi, Karthik; Chari, Suresh T.; Vege, Santhi Swaroop; Sandborn, William J.; Smyrk, Thomas C.; Loftus, Edward V.

doi:10.1002/ibd.20898

Cited by 156 publications

(80 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ravi et al 19 demonstrated that around 5.6% of patients with proven autoimmune pancreatitis had a confirmed diagnosis of IBD, compared to a prevalence of approximately 0.4%-0.5% in the general population, potentially implying a 12-15-fold increase in risk.…”

Section: 18mentioning

confidence: 96%

Inflammatory bowel disease on the risk of acute pancreatitis: A population‐based cohort study

Chen

Tseng

et al. 2016

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Section: 18mentioning

confidence: 96%

Inflammatory bowel disease on the risk of acute pancreatitis: A population‐based cohort study

Chen

Tseng

et al. 2016

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Thus, in patients with IBD-associated pancreatitis AIP could be a contributing factor. 239 Although a prospective study of pancreatitis in IBD did not show a high serum IgG4 in patients with coexisting pancreatitis, this association needs to be further explored in future prospective studies. 134 …”

Section: Hepatopancreatobiliary Diseases Possibly Associated With Ibdmentioning

confidence: 96%

Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease

Navaneethan¹,

Shen²

2010

Inflammatory Bowel Diseases

178

127

View full text Add to dashboard Cite

Diseases involving the hepatopancreatobiliary (HPB) system are frequently encountered in patients with inflammatory bowel disease (IBD). Hepatobiliary manifestations constitute some of the most common extraintestinal manifestations of IBD. They appear to occur with similar frequency in patients with Crohn's disease or ulcerative colitis. HPB manifestations may occur in following settings: 1) disease possibly associated with a shared pathogenetic mechanism with IBD including primary sclerosing cholangitis (PSC), small-duct PSC/pericholangitis and PSC/autoimmune hepatitis overlap, acute and chronic pancreatitis related to IBD; 2) diseases which parallel structural and physiological changes seen with IBD, including cholelithiasis, portal vein thrombosis, and hepatic abscess; and 3) diseases related to adverse effects associated with treatment of IBD, including drug-induced hepatitis, pancreatitis (purine-based agents), or liver cirrhosis (methotrexate), and reactivation of hepatitis B, and biologic agent-associated hepatosplenic lymphoma. Less common HPB manifestations that have been described in association with IBD include autoimmune pancreatitis (AIP), IgG4-associated cholangitis (IAC), primary biliary cirrhosis (PBC), fatty liver, granulomatous hepatitis, and amyloidosis. PSC is the most significant hepatobiliary manifestation associated with IBD and poses substantial challenges in management requiring a multidisciplinary approach. The natural disease course of PSC may progress to cirrhosis and ultimately require liver transplantation in spite of total proctocolectomy with ileal-pouch anal anastomosis. The association between AIP, IAC, and elevated serum IgG4 in patients with PSC is intriguing. The recently reported association between IAC and IBD may open the door to investigate these complex disorders. Further studies are warranted to help understand the pathogenesis of HPB manifestations associated with IBD, which would help clinicians better manage these patients. An interdisciplinary approach, involving gastroenterologists, hepatologists, and, in advanced cases, general, colorectal, and transplant surgeons is advocated.

show abstract

“…Ravi et al had detected inflammatory bowel disease in 6% of patients with proved autoimmune pancreatitis, while in Zamboni et al the incidence heightened to 17% [26,27].…”

Section: Discussionmentioning

confidence: 97%

IgG4 Sclerosing Cholangitis and Post Infantile Giant Cell Hepatitis: A Case Report of an Extraordinary Co-presentation

Elsabaawy¹,

Abdelsameea²,

Abdallah³

et al. 2017

J Mol Biomark Diagn

View full text Add to dashboard Cite

show abstract

Inflammatory bowel disease in the setting of autoimmune pancreatitis

Cited by 156 publications

References 24 publications

Inflammatory bowel disease on the risk of acute pancreatitis: A population‐based cohort study

Inflammatory bowel disease on the risk of acute pancreatitis: A population‐based cohort study

Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease

IgG4 Sclerosing Cholangitis and Post Infantile Giant Cell Hepatitis: A Case Report of an Extraordinary Co-presentation

Contact Info

Product

Resources

About